全文获取类型
收费全文 | 329022篇 |
免费 | 19545篇 |
国内免费 | 508篇 |
专业分类
耳鼻咽喉 | 4698篇 |
儿科学 | 11094篇 |
妇产科学 | 10707篇 |
基础医学 | 48934篇 |
口腔科学 | 7939篇 |
临床医学 | 27767篇 |
内科学 | 62501篇 |
皮肤病学 | 6730篇 |
神经病学 | 23891篇 |
特种医学 | 12920篇 |
外国民族医学 | 43篇 |
外科学 | 52171篇 |
综合类 | 8136篇 |
现状与发展 | 1篇 |
一般理论 | 200篇 |
预防医学 | 22890篇 |
眼科学 | 7457篇 |
药学 | 23362篇 |
中国医学 | 817篇 |
肿瘤学 | 16817篇 |
出版年
2021年 | 3258篇 |
2019年 | 3192篇 |
2018年 | 4734篇 |
2017年 | 3430篇 |
2016年 | 3861篇 |
2015年 | 4420篇 |
2014年 | 5995篇 |
2013年 | 9060篇 |
2012年 | 11748篇 |
2011年 | 12215篇 |
2010年 | 7573篇 |
2009年 | 6882篇 |
2008年 | 10990篇 |
2007年 | 11788篇 |
2006年 | 11438篇 |
2005年 | 11069篇 |
2004年 | 10652篇 |
2003年 | 9938篇 |
2002年 | 9396篇 |
2001年 | 13498篇 |
2000年 | 13810篇 |
1999年 | 11627篇 |
1998年 | 3325篇 |
1997年 | 3020篇 |
1996年 | 2862篇 |
1995年 | 2704篇 |
1994年 | 2503篇 |
1992年 | 8397篇 |
1991年 | 8523篇 |
1990年 | 8323篇 |
1989年 | 8137篇 |
1988年 | 7372篇 |
1987年 | 7114篇 |
1986年 | 6750篇 |
1985年 | 6552篇 |
1984年 | 4813篇 |
1983年 | 4173篇 |
1982年 | 2534篇 |
1979年 | 4448篇 |
1978年 | 3248篇 |
1977年 | 2748篇 |
1976年 | 2515篇 |
1975年 | 2845篇 |
1974年 | 3360篇 |
1973年 | 3368篇 |
1972年 | 3124篇 |
1971年 | 2955篇 |
1970年 | 2842篇 |
1969年 | 2586篇 |
1968年 | 2541篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
Michels Guido Horn Rudolf Helfen Andreas Hagendorff Andreas Jung Christian Hoffmann Beatrice Jaspers Natalie Kinkel Horst Greim Clemens-Alexander Knebel Fabian Bauersachs Johann Busch Hans-Jörg Kiefl Daniel Spiel Alexander O. Marx Gernot Dietrich Christoph F. 《Der Anaesthesist》2022,71(4):307-310
Die Anaesthesiologie - 相似文献
2.
Kevin Kyung Ho Choi Santosh Sanagapalli 《World journal of gastrointestinal oncology》2022,14(3):568-586
Barrett's esophagus (BE) is the precursor to esophageal adenocarcinoma (EAC). Progression to cancer typically occurs in a stepwise fashion through worsening dysplasia and ultimately, invasive neoplasia. Established EAC with deep involvement of the esophageal wall and/or metastatic disease is invariably associated with poor long-term survival rates. This guides the rationale of surveillance of Barrett’s in an attempt to treat lesions at an earlier, and potentially curative stage. The last two decades have seen a paradigm shift in management of Barrett’s with rapid expansion in the role of endoscopic eradication therapy (EET) for management of dysplastic and early neoplastic BE, and there have been substantial changes to international consensus guidelines for management of early BE based on evolving evidence. This review aims to assist the physician in the therapeutic decision-making process with patients by comprehensive review and summary of literature surrounding natural history of Barrett’s by histological stage, and the effectiveness of interventions in attenuating the risk posed by its natural history. Key findings were as follows. Non-dysplastic Barrett’s is associated with extremely low risk of progression, and interventions cannot be justified. The annual risk of cancer progression in low grade dysplasia is between 1%-3%; EET can be offered though evidence for its benefit remains confined to highly select settings. High-grade dysplasia progresses to cancer in 5%-10% per year; EET is similarly effective to and less morbid than surgery and should be routinely performed for this indication. Risk of nodal metastases in intramucosal cancer is 2%-4%, which is comparable to operative mortality rate, so EET is usually preferred. Submucosal cancer is associated with nodal metastases in 14%-41% hence surgery remains standard of care, except for select situations. 相似文献
3.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
4.
5.
Phoebe Hammer Kevin White Stephanie Mengden Vessy Korcheva Philipp W. Raess 《Journal of cutaneous pathology》2019,46(5):343-346
Cutaneous leiomyomas are rare benign smooth‐muscle tumors. These lesions are distinguished based on their cell of origin and are subclassified as pilar leiomyoma, angioleiomyoma, and genital‐type leiomyoma. Nipple leiomyoma is the least common genital‐type leiomyoma, arising from the dartoic muscle cell of the nipple. Histologic examination of the lesion is necessary for definitive diagnosis, and these uncommon tumors can pose a diagnostic challenge. We describe herein a series of six nipple leiomyomas with a spectrum of histologic appearances. 相似文献
6.
7.
8.
9.
10.